We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

193 hedge funds and large institutions have $2.43B invested in Celldex Therapeutics in 2015 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 61 increasing their positions, 54 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

172% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 18

64% more capital invested

Capital invested by funds: $1.48B → $2.43B (+$952M)

18% more funds holding

Funds holding: 163 → 193 (+30)

13% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 54

16% less call options, than puts

Call options by funds: $51.6M | Put options by funds: $61.4M

Holders
193
Holders Change
+30
Holders Change %
+18.4%
% of All Funds
5.14%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
49
Increased
61
Reduced
54
Closed
18
Calls
$51.6M
Puts
$61.4M
Net Calls
-$9.78M
Net Calls Change
+$7.85M

Top Buyers

1
First Trust Advisors
First Trust Advisors
Illinois
+$113M
2
Millennium Management
Millennium Management
New York
+$47.5M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$25.9M
4
Deutsche Bank
Deutsche Bank
Germany
+$21.4M
5
BIT
BlackRock Institutional Trust
California
+$17M

Top Sellers

1
O
OrbiMed
New York
-$34.9M
2
Bank of New York Mellon
Bank of New York Mellon
New York
-$23.5M
3
Franklin Resources
Franklin Resources
California
-$21.4M
4
CCI
Columbus Circle Investors
-$16.2M
5
CA
Commerzbank Aktiengesellschaft
Germany
-$12.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$405M +$25.9M +72,537 +8%
O
2
OppenheimerFunds
New York
$254M -$4.24M -11,861 -2%
Franklin Resources
3
Franklin Resources
California
$242M -$21.4M -59,795 -9%
Vanguard Group
4
Vanguard Group
Pennsylvania
$170M +$16.3M +45,683 +13%
First Trust Advisors
5
First Trust Advisors
Illinois
$132M +$113M +315,796 New
BFA
6
BlackRock Fund Advisors
California
$104M +$8.99M +25,144 +11%
BIT
7
BlackRock Institutional Trust
California
$83.3M +$17M +47,602 +31%
CWAM
8
Columbia Wanger Asset Management
Illinois
$78.1M -$9.44M -26,400 -12%
Lord, Abbett & Co
9
Lord, Abbett & Co
New Jersey
$64.9M -$8.17M -22,851 -13%
State Street
10
State Street
Massachusetts
$64.4M -$3M -8,400 -5%
Millennium Management
11
Millennium Management
New York
$57.7M +$47.5M +132,813 +2,545%
TCM
12
TimesSquare Capital Management
New York
$51.4M -$6.33M -17,686 -13%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$42.2M -$23.5M -65,809 -39%
Deutsche Bank
14
Deutsche Bank
Germany
$37.7M +$21.4M +59,919 +198%
UBS AM
15
UBS AM
Illinois
$31.6M +$4.69M +13,100 +21%
Northern Trust
16
Northern Trust
Illinois
$28.6M +$825K +2,307 +3%
CCI
17
Columbus Circle Investors
$26.5M -$16.2M -45,153 -42%
Morgan Stanley
18
Morgan Stanley
New York
$23.8M -$1.32M -3,700 -6%
TCMG
19
TSP Capital Management Group
New Jersey
$22.9M – – –
Invesco
20
Invesco
Georgia
$21.2M +$4.91M +13,735 +37%
FCM
21
Frontier Capital Management
Massachusetts
$18.3M -$12.5M -34,939 -44%
Capital World Investors
22
Capital World Investors
California
$17.5M +$5.72M +16,000 +62%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$16.9M +$2.04M +5,690 +16%
O
24
OrbiMed
New York
$16.7M -$34.9M -97,480 -71%
First Eagle Investment Management
25
First Eagle Investment Management
New York
$15.6M – – –
1
2 3 4 5

CLDX Hedge Fund Activity: Q1 2015 in Review

193 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2015, worth a combined $2.43B — up 64% from $1.48B a quarter earlier.

Buyers outnumbered sellers: 49 funds opened new CLDX positions and 18 closed out — a net gain of 31 holders — while 61 added to existing stakes and 54 trimmed.

The largest buyer was First Trust Advisors, opening a new position worth an estimated $113M. The largest seller was OrbiMed, cutting an estimated $34.9M.

  • 193 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2015, up from 163 in Q4 2014.
  • Funds reported $2.43B of Celldex Therapeutics stock for Q1 2015, up 64% quarter-over-quarter.
  • 49 funds opened new Celldex Therapeutics positions in Q1 2015 and 18 closed out, a net change of +31 holders.
  • The largest Celldex Therapeutics buyer in Q1 2015 was First Trust Advisors, an estimated $113M added.
  • The largest Celldex Therapeutics seller in Q1 2015 was OrbiMed, an estimated $34.9M sold.

Based on aggregated 13F filings for Q1 2015.